| Literature DB >> 10785263 |
P Venugopal1, S Sivaraman, X K Huang, J Nayini, S A Gregory, H D Preisler.
Abstract
Anti-CD20 antibody is an established treatment for low-grade non-Hodgkin's lymphoma (NHL). Augmenting the expression of CD20 antigen on the tumor cells may increase the cell kill and therefore increase the effectiveness of the antibody. To study this, we incubated peripheral blood lymphocytes from CLL patients with the following cytokines: EPO, SCF, TNFalpha, TGFbeta, GMCSF, TPO, IL-1, IL-2, IL-3, IL-4, GCSF. CD20 expression was studied by flow cytometry at baseline, 24 and 72 h after exposure to these cytokines. Upregulation of CD20 antigen expression was observed with IL-4, TNFalpha and GMCSF.Entities:
Mesh：
Substances：
Year: 2000 PMID： 10785263 DOI： 10.1016/s0145-2126(99)00206-4
Source DB: PubMed Journal: Leuk Res ISSN： 0145-2126 Impact factor: 3.156